Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania

Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania

Abstract Tanzania adopted a Dolutegravir (DTG)-based regimen as first-line treatment in 2019 following the World Health Organization recommendation. Data on the DTG safety profile from sub-Saharan Africa including Tanzania are limited. We investigated the incidence of DTG-related adverse events (AEs...

Full description

Bibliographic Details
Main Authors: Adam Fimbo, Yonah H. Mwalwisi, Kissa Mwamwitwa, Damas Matiko, Elirehema Mfinanga, Johnson Lyimo, Amon Sabasaba, Seth Missago, Elias Bukundi, Goodluck Gotora, Dorice Respick, Alex Nkayamba, Emmanuel Masunga, Rajabu Hussein Mnkugwe, Peter P. Kunambi, Castory Munishi, Christine Chiedza Musanhu, Omary M. S. Minzi, Eulambius M. Mlugu
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-51144-7

Similar Items

Similar Items